Incretin Monogamy Is A Social Construct

He swore Semaglutide was forever. Then Tirzepatide. Now there's a triple agonist in the group chat and someone is crying in the background.

Filed under Semaglutide ·Tirzepatide ·Survodutide · #glp-1 ·#stack-life ·#cope

Active Compounds

Semaglutide · GLP-1 Receptor Agonist

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.

Tirzepatide · Dual GIP/GLP-1 Receptor Agonist

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

RX: Semaglutide · Tirzepatide · Survodutide
Dosage: whichever vial is newest
Half-life: until the next receptor gets added
Source: manual
Tags: glp-1 , stack-life , cope
Stamped: 2026-05-31 · Cycle 022
Lot #: LOT-20260531T15:35:23.426Z